Pfizer and Novartis are set to team up in a non-exclusive partnership aimed at the clinical development of one or more combo therapies for the treatment of non-alcoholic steatohepatitis (NASH).
Under the partnership, the pair with investigate the efficacy of three Pfizer candidates in combination with Novartis’s non-bile acid, farnesoid X receptor (FXR) agonist tropifexor.
Reageer